Introduction
============

Cervical cancer (CC) is the fourth most common cancer in women worldwide, with 85% of cases occurring in developing countries.[@b1-ijwh-10-187] Persistent human papillomavirus (HPV) infection is the prerequisite for the development of cervical intraepithelial neo-plasia (CIN) and CC.[@b2-ijwh-10-187] Following the trend of HPV infection over time and identifying persistent infections constitute one of the fundamental bases for CC prevention.[@b3-ijwh-10-187]

In low-to-middle income countries (LMIC), visual inspection with acetic acid (VIA) and visual inspection with Lugol's iodine (VILI) are the recommended tools for primary CC screening. These methods require a pelvic examination and the presence of an experienced health-care professional. Follow-up for screen-positive women based on a pelvic examination is difficult to implement in LMIC, where the availability of resources is hard to ensure.[@b4-ijwh-10-187]

It is paramount to develop a follow-up strategy that relies on economical and logistically simple procedures in low-income settings. The recent introduction of rapid polymerase chain reaction (PCR) tests makes it possible to detect viral infection within an hour of sample collection, thus enabling to further manage HPV-positive women on the same day.[@b5-ijwh-10-187] In addition, HPV testing can be performed on self-collected vaginal samples (Self-HPV) while guaranteeing the same diagnostic accuracy as physician-collected samples (Dr-HPV).[@b6-ijwh-10-187] By circumventing the need of a clinic-based pelvic examination, Self-HPV offers the opportunity to potentially break down some of the barriers to follow-up visits attendance. As the current evidence has been focusing primarily on the use of Self-HPV for primary CC screening, only a few data on the use of Self-HPV for the follow-up of HPV-positive women are available.

Considering the limited availability of resources and the high risk of loss to follow-up in LMIC, it is of utmost interest to develop an effective strategy for the detection of residual or recurrent disease while guaranteeing a high patient participation in care. Our aim was to compare the performance of Self-HPV and Dr-HPV for the follow-up of HPV-positive women at 6 and 12 months after baseline screening.

Methods
=======

Study setting
-------------

This study took place at the Dschang District Hospital, which is located in Cameroon's Western region and counts \~250,000 inhabitants. In July 2015, all women aged 30--49 years were recruited in a CC screening campaign. Exclusion criteria were ongoing pregnancy and previous total hysterectomy. A total of 1,012 women were recruited in the study. The participants performed HPV self-sampling (Self-HPV) for primary screening. The samples were promptly analyzed using a point-of-care assay (GeneXpert^®^IV; Cepheid, Sunnyvale, CA, USA). All women with a positive high-risk HPV test underwent a gynecological examination including VIA and VILI. When VIA revealed a pathological area, a biopsy of the suspected lesion was taken. If VIA revealed no pathological area, a 6 o'clock biopsy sample was taken. Endocervical brushing was performed on all HPV-positive women. Treatment, if needed, was performed using thermoablation. The HPV test, triage with VIA and VILI, and treatment were performed within the same day. Additionally, all study participants were asked to complete a questionnaire on sociodemographics as well as obstetric and gynecological histories.

Study design
------------

Women positive for HPV at primary screening were asked to come for a follow-up visit at 6 and 12 months. The participants were called by the local medical personnel for their follow-up visits. Women were invited to perform Self-HPV using a dry swab, which was subsequently immersed in 5 mL of an NaCl 0.9% solution and vortexed for 10 seconds. One milliliter of this solution was then placed into a GeneXpert cartridge and run on the four-module GeneXpert machine. The physician also collected a sample for HPV testing and cytology. Cervical cells were collected using a Cervex-Brush Combi (Rovers, Oss, the Netherlands) as recommended by the European guidelines[@b7-ijwh-10-187] and, then, transferred into a BD SurePath™ collection vial containing a preservative fluid (BD, Franklin Lakes, NJ, USA).

The sample was vortexed for 10 seconds, and an aliquot of 1 mL was placed in the GeneXpert cartridge. Each sample was analyzed within 20 minutes from its collection. The rest of the sample was transported to Geneva, Switzerland, for cytological specimen analysis. All women, regardless of the HPV test result, underwent a pelvic examination with VIA and VILI. A biopsy and ECC sample were collected from women presenting with a pathological VIA, as well as from all the previously treated participants, to assess their disease status.

HPV testing
-----------

The GeneXpert HPV assay used for HPV testing consists of a real-time PCR that uses the detection of a human reference gene (hydroxymethylbilane synthase) and an internal probe check control for specimen adequacy. The probe check control was used to verify reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability. The Xpert test included reagents for the simultaneous detection of 14 high-risk HPV (hrHPV) genotypes (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68). The assay uses multiple fluorescent channels for the detection of individual HPV types, pooled HPV types, and the human reference gene. Each fluorescent channel has specific cutoff parameters for target detection and validity. If a sufficient amount of signal is detected for the human reference gene, the assay results are reported as positive. Additionally, HPV-16, pooled HPV-18/45, and pooled other hrHPV types detected by the assay are reported separately as either positive or negative. The test results are available within 50 minutes of the cartridge's introduction into the device.

Cytology
--------

Thin-layer slides were prepared from the remaining in the preservative fluid sample using the BD Totalys™ SlidePrep processor (BD) located at Cytopath-Unilabs Laboratories, Geneva, Switzerland. All slides were read by a cytopathologist (PV) and were classified according to the Bethesda nomenclature system. Cytology results were considered as the "reference diagnosis" to determine the performance of Self- and Dr-HPV. Two different cutoffs were used to assess the women's disease status. The first cutoff was set at the presence of low-grade squamous intraepithelial lesion or worse (LSIL+), whereas the second cutoff was the presence of high-grade squamous intraepithelial lesion or worse (HSIL+).

Thermoablation
--------------

The procedure consists in the application of a probe heated to 100°C on the cervix for \~60 seconds, which achieves a tissue destruction of 5--7 mm in depth. An appropriately-sized probe was selected based on the area of the pathological cervical tissue. Several applications were performed, if needed, to cover the entire pathological area.

Data management
---------------

A personalized electronic medical chart including sociodemographic and medical information was created using the secuTrial^®^ (interActive systems, Berlin, Germany) online database to collect and manage data at baseline screening and follow-up.

Statistical analyses
--------------------

Data analysis was performed using the Stata Statistical Software Release 14 (StataCorp LP, College Station, TX, USA). Quantitative variables were expressed as mean and SD, and qualitative variables were expressed as percentage, unless otherwise stated. McNemar's test was used to compare the performance of the tests. All tested hypotheses were two sided, and *P*-values \<0.05 were considered statistically significant.

Sensitivity, specificity, positive predictive value, and negative predictive value (NPV) for the detection of HSIL were calculated for Self-HPV and Dr-HPV, using cytology as the standard reference. Agreement between the Self-HPV and the Dr-HPV was assessed using the *κ* values, and their 95% CIs were calculated. *κ* values were calculated by obtaining the difference between the observed and the expected agreement and by standardizing the obtained value on a −1 to 1 scale. *κ* values were interpreted according to a commonly used scale. For *κ* values \<0, the agreement is considered to be less than what would be expected by chance; for *κ* values 0.01--0.20, only a slight agreement is present; for *κ* values 0.21--0.40, the agreement is considered to be fair; for *κ* values 0.41--0.60, the agreement is said to be moderate; for *κ* values 0.61--0.80, the agreement is considered substantial; and finally, for *κ* values 0.81--0.99, the agreement is said to be almost perfect.[@b8-ijwh-10-187]

Ethics approval and informed consent
------------------------------------

This study was approved by the Ethical Cantonal Board of Geneva, Switzerland (Commission Cantonale d'Ethique de la Recherche), with the identification number 15-068. All participants have signed a written informed consent form prior to taking part in the study. All participants have consented to having duplicate analyses of their specimens to fulfill the study's purpose.

Results
=======

Participants' characteristics
-----------------------------

All of the 188 HPV-positive participants were invited to attend the 6 and 12 months control visits. Their mean age was 38.7±5.6 years. They had an average of 3.9±2.8 sexual partners, and 175/188 (93.1%) of them were married or in a stable relationship. A total of 116/187 (62.0%) of the participants had a high-school diploma. The detection rate of CIN grade 2 or worse (CIN 2+) at baseline was 19/1,012 (1.9%). The participants' sociodemographics and clinical characteristics at baseline are reported in [Table 1](#t1-ijwh-10-187){ref-type="table"}. Follow-up was pursued for 154/188 (81.9%) patients at 6 months and 131/188 (69.7%) patients at 12 months.

Performance of Self- and Dr-HPV at 6 months
-------------------------------------------

Using cytology as the standard reference, Self-HPV had a sensitivity of 84.6% (95% CI 49.0--96.9), whereas Dr-HPV had a sensitivity of 92.3% (95% CI 53.1--99.2) for the detection of LSIL+ at 6 months (*P*=1.000). The specificity of Self-HPV for the detection of LSIL+ at 6 months was 68.1% (95% CI 59.9--75.3), whereas Dr-HPV had a specificity of 75.7% (95% CI 67.8--82.2) (*P*=0.043).

The sensitivity of Self-HPV for the detection of HSIL+ at 6 months was 88.9% (95% CI 37.4--99.1), whereas Dr-HPV achieved a sensitivity of 100 (*P*=1.000). The specificity of Self-HPV for the detection of HSIL+ at 6 months was 66.9% (95% CI 58.7--74.1), whereas the specificity of Dr-HPV was 74.3% (95% CI 66.5--80.8) (*P*=0.043). The performance of Self- and Dr-HPV at 6 months is reported in [Table 2](#t2-ijwh-10-187){ref-type="table"}.

Performance of Self- and Dr-HPV at 12 months
--------------------------------------------

Using cytology as the standard reference, Self-HPV had a sensitivity of 85.7% (95% CI 25.7--99.0), whereas Dr-HPV had a sensitivity of 71.4% (95% CI 21.5--95.8) for the detection of LSIL+ at 12 months (*P*=1.000). The specificity of Self-HPV for the detection of LSIL+ at 12 months was 66.1% (95% CI 57.2.8--74.0), whereas Dr-HPV had a specificity of 79.0% (95% CI 70.9--85.4) (*P*=0.003).

The sensitivity of Self-HPV for the detection of HSIL+ at 12 months was 83.3% (95% CI 18.6--99.1), whereas Dr-HPV achieved a sensitivity of 71.4 (95% CI 21.5--95.8) (*P*=1.000). The specificity of Self-HPV for the detection of HSIL+ at 12 months was 65.6% (95% CI 56.7--73.5), whereas the specificity of Dr-HPV was 79.0% (95% CI 70.9--85.4) (*P*=0.002). The performance of Self- and Dr-HPV at 12 months is reported in [Table 3](#t3-ijwh-10-187){ref-type="table"}.

Performance of Self- and Dr-HPV according to baseline treatment status
----------------------------------------------------------------------

Among women who underwent thermoablation at baseline screening, the sensitivity of HPV testing using Dr-HPV specimens was identical to that achieved using Self-HPV specimens. Nevertheless, the specificity of Dr-HPV was significantly higher than Self-HPV (*P*=0.003) ([Table 4](#t4-ijwh-10-187){ref-type="table"}). Among untreated women, data were difficult to interpret because of the lack of power and, therefore, have not been displayed in [Table 4](#t4-ijwh-10-187){ref-type="table"}. There was no difference between treated and untreated women in terms of the tests' performance.

HPV positivity agreement between Self-HPV and Dr-HPV
----------------------------------------------------

The overall agreement statistics for Self- and Dr-HPV at 6 and 12 months was satisfactory, with a *κ* value of 0.62 and 0.52, respectively.

*κ* values were stratified by the women's sociodemographic and clinical characteristics. At 6 months, the *κ* value for Self-HPV and Dr-HPV varied between 0.35 and 0.78. For women positive for HPV-16, the *κ* value was 0.76 (95% CI 0.60--0.92). For women aged 40--44 years, the *κ* value was 0.77 (95% CI 0.42--1.12). At 12 months, the *κ* value for Self-HPV and Dr-HPV varied between 0.33 and 0.75. Women positive for other hrHPV types had a *κ* value of 0.63 (95% CI 0.51--0.79), and women with parity \>5 had a *κ* value for Self-HPV and Dr-HPV of 0.75 (95% CI 0.35--1.15). The *κ* values for Self-HPV and Dr-HPV stratified by the women's clinical and sociodemographic characteristics at 6 and 12 months are reported in [Figures 1](#f1-ijwh-10-187){ref-type="fig"} and [2](#f2-ijwh-10-187){ref-type="fig"}, respectively.

Discussion
==========

This study compared the performance of self- and physician-collected samples for the detection of high-grade cervical lesions at 6 and 12 months following a CC screening campaign. While at 6 month Self-HPV showed a better performance in terms of LSIL+ and HSIL+ detections than Self-HPV, the latter achieved a sensitivity of 85.7% (95% CI 25.7--99.0) and 83.3% (95% CI 18.6--99.1), for the detection of LSIL+ and HSIL+, respectively, at 12 months, compared to a sensitivity of 71.4% (95% CI 21.5--95.8) achieved by Dr-HPV using the two respective cutoffs. Furthermore, the high NPV of the two tests supports the use of these strategies for the exclusion of the disease in the follow-up of HPV-positive women.

Among women treated with thermoablation, we found that Self-HPV was less specific, although the sensitivity between the two strategies (Self- vs Dr-HPV) did not differ significantly. Similarly, Taylor et al[@b9-ijwh-10-187] found that, among women treated with cryotherapy, HPV testing performed on self-collected samples was significantly less specific when compared with HPV testing performed on clinician-collected samples for the detection of CIN. The authors suggest that the lower specificity of Self-HPV may be due to the presence of residual HPV-infected cells in the vagina, despite the clearance of the HPV infection on the cervical transformation zone. Nonetheless, one relevant detail is that HPV testing in the study by Taylor et al was performed using the Hybrid Capture 2 HPV DNA assay, which is known to be less sensitive than the machine GeneXpert we used (81.6 vs 90.8%, *P*=0.004).[@b10-ijwh-10-187] Speaking in favor of Self-HPV is a prospective study showing that Self-HPV is as accurate as clinician-directed lavages in describing the natural history of the HPV infection over time.[@b11-ijwh-10-187]

The *κ* values found in our study show a moderate-to-substantial agreement between Self-HPV and Dr-HPV when stratified by the women's sociodemographic and clinical characteristics. The fact that the *κ* values do not follow a linear trend according to the participants' characteristics makes our results difficult to interpret. Previous studies have reported a similar agreement rate between self- and physician-collected swabs in primary screening, their *κ*-statistic varying between 0.54 and 0.62.[@b12-ijwh-10-187],[@b13-ijwh-10-187] Similar to Johnson et al, we obtained a substantially improved agreement between Self- and Dr-HPV test results for women who tested positive for HPV-16 (97.7%).[@b13-ijwh-10-187],[@b14-ijwh-10-187]

We found that Self-HPV had a lower specificity among treated women. This issue could be solved by pairing Self-HPV with either cytology or VIA/VILI for the follow-up of previously treated women. As a previous cervical treatment status dictates the necessity to undergo a gynecological examination, in such context, Self-HPV could serve as a supplementary tool, rather than a substitute of the pelvic examination-based strategies. Increasing evidence has shown that HPV testing used on women treated with ablative techniques, such as cryotherapy, vaunts a high sensitivity and an NPV for the detection of residual or recurrent disease.[@b14-ijwh-10-187] In a study comparing different follow-up techniques for women treated with cryotherapy, Omenge Orang'o et al[@b15-ijwh-10-187] demonstrated that, although at the price of a lower specificity when compared with cytology and VIA, HPV testing alone has the best sensitivity for the detection of CIN 2+.

A recently published review has concluded that self-sampling is generally well accepted by women.[@b16-ijwh-10-187] The main reasons for the better acceptance of Self-HPV compared to Dr-HPV are its ease of use and respect of the women's intimacy.[@b16-ijwh-10-187] This high acceptance could potentially reduce the loss to follow-up that is currently responsible for low program impact in developing countries.[@b17-ijwh-10-187]

One strength of our study is that all patients benefited from cytology at 6 and 12 months, thus allowing us to validate the performance of the two tests using cytology as the reference diagnosis. To our knowledge, this is one of the first studies to compare the performance of Self- and Dr-HPV for the follow-up of screen-positive women with that of women treated by thermoablation in a low-resource setting.

Limitations that need to be addressed are the small sample size and the 30.3% loss to follow-up rate at 12 months, which limits the generalization of our findings to the rest of the population. Larger, prospective cohort studies are needed to confirm our results by comparing them directly with other follow-up strategies, such as VIA/VILI and cytology. Another limitation is the discrepancy between the use of NaCl 0.9% and the SurePath medium for HPV analysis of Self-HPV and Dr-HPV, respectively. Our previous experience has demonstrated that the use of NaCl 0.9% is a valid medium for HPV analysis on Self-HPV.[@b18-ijwh-10-187] The use of this medium, however, has not yet been proven effective for Dr-HPV. Therefore, the NaCl 0.9% was used for Self-HPV sample analysis, whereas the SurePath medium, as recommended by the manufacturers, was used for the analysis of Dr-HPV samples.

Conclusion
==========

The use of HPV testing on self-collected samples is a valuable option for the follow-up of HPV-positive women in LMIC. Although the specificity of Dr-HPV is slightly superior, the advantages of Self-HPV seem to outweigh its flaws, making it a valuable tool to break down the main barrier to follow-up attendance in LMIC.

Data availability
=================

The data are securely stored in the online database SecuTrial. Data will be available upon request.
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###### 

Sociodemographic and clinical characteristics of the study population

  Variable                                                                           n (%)
  ---------------------------------------------------------------------------------- ------------
  Age (years), mean ± SD                                                             38.7±5.6
  Age at first sexual intercourse (years), mean ± SD                                 17.9±2.7
  Gestity, mean ± SD                                                                 5.0±2.2
  Parity, mean ± SD                                                                  4.0±1.9
  Number of sexual partners, mean ± SD                                               3.9±2.8
  Marital status                                                                     
   Single                                                                            13 (6.9)
   With a partner                                                                    175 (93.1)
  Education level                                                                    
   None                                                                              1 (0.5)
   Elementary school                                                                 39 (20.9)
   Apprenticeship                                                                    3 (1.6)
   High school                                                                       116 (62.0)
   University                                                                        27 (14.4)
   Others                                                                            1 (0.5)
  Employment status                                                                  
   Employed                                                                          121 (64.4)
   Farmer                                                                            12 (6.4)
   Housewife                                                                         48 (25.5)
   Others                                                                            7 (3.7)
  Contraception                                                                      
   None                                                                              141 (75.0)
   Pill                                                                              3 (1.6)
   IUD                                                                               4 (2.1)
   Injection                                                                         10 (5.3)
   Condom                                                                            21 (11.2)
   Others                                                                            9 (4.8)
  HPV test result at baseline screening[a](#tfn2-ijwh-10-187){ref-type="table-fn"}   
   HPV-16                                                                            20 (10.7)
   HPV-18/45                                                                         42 (22.5)
   Other hrHPV                                                                       125 (66.8)
  Histological diagnosis at baseline                                                 
   Negative                                                                          150 (82.9)
   CIN 1                                                                             10 (5.5)
   CIN 2                                                                             3 (1.7)
   CIN 3                                                                             15 (8.3)
   Invasive carcinoma                                                                1 (0.6)
  Treatment by thermoablation at baseline                                            
   Yes                                                                               121 (64.4)
   No                                                                                67 (35.6)

**Notes:** CIN 1/2/3, CIN grade 1/2/3.

HPV self-sample test result.

**Abbreviations:** CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; hrHPV, high-risk HPV; IUD, intrauterine device; SD, standard deviation.

###### 

Performance of Self-HPV and Dr-HPV at 6 months

  Variable                  Sensitivity, % (95% CI)   Specificity, % (95% CI)   PPV, % (95% CI)     NPV, % (95% CI)
  ------------------------- ------------------------- ------------------------- ------------------- -------------------
  Abnormal cytology LSIL+                                                                           
   Self-HPV                 84.6 (49.0--96.9)         68.1 (59.9--75.3)         19.6 (11.0--32.6)   98.0 (92.0--99.5)
   Dr-HPV                   92.3 (53.1--99.2)         75.7 (67.8--82.2)         26.1 (15.1--41.2)   99.1 (93.5--99.9)
  Abnormal cytology HSIL+                                                                           
   Self-HPV                 88.9 (37.4--99.1)         66.9 (58.7--74.1)         14.3 (7.1--26.5)    99.0 (92.9--99.9)
   Dr-HPV                   100                       74.3 (66.5--80.8)         19.6 (10.2--34.1)   100

**Abbreviations:** HPV, human papillomavirus; HSIL+, high-grade squamous intraepithelial lesion or worse; LSIL+, low-grade squamous intraepithelial lesion or worse; NPV, negative predictive value; PPV, positive predictive value; Self-HPV, HPV test result of the self-taken sample; Dr-HPV, HPV test result of the physician-taken sample.

###### 

Performance of Self-HPV and Dr-HPV at 12 months

  Variable                  Sensitivity, % (95% CI)   Specificity, % (95% CI)   PPV, % (95% CI)     NPV, % (95% CI)
  ------------------------- ------------------------- ------------------------- ------------------- -------------------
  Abnormal cytology LSIL+                                                                           
   Self-HPV                 85.7 (25.7--99.0)         66.1 (57.2--74.0)         12.5 (5.56--25.8)   98.8 (91.6--99.8)
   Dr-HPV                   71.4 (21.5--95.8)         79.0 (70.9--85.4)         16.1 (6.5--34.6)    98.0 (92.2--99.5)
  Abnormal cytology HSIL+                                                                           
   Self-HPV                 83.3 (18.6--99.1)         65.6 (56.7--73.5)         10.4 (4.3--23.3)    98.8 (91.6--99.8)
   Dr-HPV                   71.4 (21.5--95.8)         79.0 (70.9--85.4)         16.1 (6.5--34.6)    99.0 (93.0--99.8)

**Notes:** Self-HPV, HPV test result of the self-taken sample; Dr-HPV, HPV test result of the physician-taken sample.

**Abbreviations:** HPV, human papillomavirus; HSIL+, high-grade squamous intraepithelial lesion or worse; LSIL+, low-grade squamous intraepithelial lesion or worse; NPV, negative predictive value; PPV, positive predictive value.

###### 

Comparison of Self-HPV and Dr-HPV test performance for the detection of HSIL at 12 months among women treated with thermoablation

  Variable        Cytology   Sensitivity, % (95% CI)   *P*-value           Specificity, % (95% CI)   *P*-value           
  --------------- ---------- ------------------------- ------------------- ------------------------- ------------------- ---------------------------------------------------
  Treated women   n=4        n=82                                                                                        
  Self-HPV                                                                                                               
   Positive       3          28                        75.0 (28.9--96.6)   1.000                     65.9 (55.1--75.2)   0.003[\*](#tfn8-ijwh-10-187){ref-type="table-fn"}
   Negative       1          54                                                                                          
  Dr-HPV                                                                                                                 
   Positive       3          14                        75.0 (28.9--96.6)                             82.9 (73.2--89.7)   
   Negative       1          68                                                                                          

**Notes:** Self-HPV, HPV test result of the self-taken sample; Dr-HPV, HPV test result of the physician-taken sample.

*P*-value \<0.05.

**Abbreviation:** HPV, human papillomavirus.
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